Glucagon-like peptide-1 receptor agonists, commonly prescribed for weight loss and type 2 diabetes like Zepbound and Wegovy, significantly improve obstructive sleep apnea associated with obesity primarily by reducing fat in the neck, throat, and tongue, according to a research review published September 3 in JAMA Otolaryngology.
How GLP-1 Medications Impact Obstructive Sleep Apnea
Obstructive sleep apnea occurs when throat muscles and tissues relax during sleep, which blocks the airway. According to findings from the National Council on Aging, weight loss is frequently recommended alongside standard continuous positive airway pressure therapy because shedding pounds reduces fat deposits around the neck and tongue. The JAMA Otolaryngology review examined medical databases including PubMed, Cochrane Library, ClinicalTrials.gov, and Google Scholar for studies published between 2016 and 2025.
Data from the SURMOUNT-OSA phase 3 trials showed that tirzepatide reduced the apnea-hypopnea index by approximately 20 to 24 events per hour compared to a placebo. Furthermore, roughly 42% to 50% of trial participants achieved full clinical remission of their symptoms. Liraglutide demonstrated similar improvements in both AHI scores and weight reduction during the SCALE Sleep Apnea trial.
Did you know? Improvements in sleep apnea severity can appear as early as four weeks into treatment with tirzepatide—often before patients reach their maximum weight loss milestones, suggesting benefits beyond simple mass reduction.
Comparing GLP-1 Therapy to Standard CPAP Treatment
While medications show substantial promise, medical specialists emphasize that continuous positive airway pressure machines remain the superior and primary treatment option. Sleep medicine specialist Ruchir P. Patel, MD, FACP, vice president and senior medical director at Inspire Medical Systems, noted that while tirzepatide addresses obesity as a major risk factor, it cannot correct structural airway anomalies completely.
“There are other factors involved in the development of OSA, including just structural anatomy unrelated to fat deposits that cannot be addressed by weight loss,” Patel told Healthline. He added that significant weight loss does not always resolve the condition entirely, meaning patients with severe disease remain at risk even after shedding pounds.
Clinical Guidelines and Financial Considerations
Board-certified surgeon and weight loss specialist James J. Chao, MD, FACS, co-founder and chief medical officer at VedaNu Wellness, advises patients to maintain their CPAP routines while integrating new pharmaceutical treatments. “Once you’ve been treated for 12 months, you’ll need to repeat the sleep study to see if you’ve achieved a reduction in apnea,” Chao told Healthline.
Zepbound, which contains tirzepatide and acts on both GLP-1 and GIP receptors, stands as the sole weight loss medication currently approved by the Food and Drug Administration specifically for moderate to severe OSA in adults with obesity. However, Chao noted that monthly expenses can hover around $1,000, with insurance reimbursement depending heavily on physician coding.
Pro Tip: Patients considering a transition or addition to their treatment regimen should consult a physician to evaluate whether weight loss makes them better candidates for alternative interventions, such as hypoglossal nerve stimulation.
Frequently Asked Questions
Are GLP-1 medications FDA-approved for sleep apnea?
Yes. Zepbound, which contains tirzepatide, is approved by the Food and Drug Administration to treat moderate to severe obstructive sleep apnea in adults with obesity.
Can I stop using my CPAP machine once I start taking Wegovy or Zepbound?
No. Physicians stress that patients must continue using CPAP therapy until a doctor officially confirms disease remission using a formal sleep study after at least a year of evaluation.
How do these drugs reduce sleep apnea symptoms?
According to clinical reviews, GLP-1 receptor agonists promote significant weight loss that decreases fat volume in the neck, throat, and tongue, thereby keeping the upper airway open during sleep.
Join the Conversation: Have you or a loved one discussed pharmaceutical options for sleep apnea management with a specialist? Share your thoughts or questions in the comments below, and subscribe to our newsletter for the latest updates in clinical research.
Worth a look